SCHEMBL2942579

SCHEMBL2942579

NS(=O)(=O)c1ccc(CNc2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.67
NTRK3 Q16288 3/20 0.67
NTRK2 Q16620 3/20 0.67
FYN P06241 3/20 0.62
PIM1 P11309 10/20 0.57
DYRK1A Q13627 4/20 0.54
DYRK2 Q92630 4/20 0.54
CCNA2 P20248 3/20 0.54
CDK2 P24941 3/20 0.54
CDK5 Q00535 3/20 0.54
CDK5R1 Q15078 3/20 0.54
DYRK1B Q9Y463 3/20 0.54
CCNT1 O60563 2/20 0.54
CDK9 P50750 2/20 0.54
KCNH2 Q12809 2/20 0.53
DYRK3 O43781 1/20 0.50
PIM3 Q86V86 1/20 0.50
PIM2 Q9P1W9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949572 0.87 NTRK1 (0.69) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL2947680 0.87 PIM1 (0.77) NTRK1NTRK3NTRK2PIM1KCNH2
SCHEMBL13234539 0.86 NTRK1 (0.70) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL2943833 0.85 FYN (0.71) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL1053101 0.84 NTRK1 (0.66) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL2951116 0.84 FYN (0.67) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL102929 0.83 NTRK1 (0.64) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL2945213 0.82 NTRK1 (0.68) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL2943263 0.81 NTRK1 (0.66) NTRK1NTRK3NTRK2FYNPIM1
SCHEMBL1055209 0.81 NTRK1 (0.66) NTRK1NTRK3NTRK2FYNPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 NTRK1 486/4885NTRK3 623/4885NTRK2 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.